Session 1: Standardization and Validation of Immunologic Biomarkers

- REMARK criteria has become the <u>standard for publication</u> of biomarker studies-why do immunotherapy biomarker studies not adhere? (McShane et al JNCI, 2005)
 - Description of reproducibility, description of controls and quality control, sample preparation standards
- What should be expected of a laboratory that performs immunologic assays for clinical trials?
 - FDA draft guidance for therapeutic cancer vaccines: at least 2 assays; assay parameters/controls should be clearly described (Sept. 2009)
 - QA/QC, reference populations screening of reagents, assay performance characteristics
 - How to balance standardized assays for immune response with research questions?